Sunshine Biopharma Competitors and Similar CompaniesClear all

Sunshine Biopharma's competitors and similar companies include Debiopharm, Agios Pharmaceuticals, Helsinn Group and Turning Point Therapeutics.

	Sunshine Biopharma Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.	Debiopharm Debiopharm is a biopharmaceutical company specializing in oncology and bacterial infections.	Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.	Helsinn Group Helsinn Group is a pharmaceutical company that focuses on therapeutic and supportive care products for cancer.	Turning Point Therapeutics Turning Point Therapeutics (TP Therapeutics) is a precision oncology company that is engaged in medicine discovery for cancer and other diseases.
Founding Date	Founding Date 2006	Founding Date 1979	Founding Date 2008	Founding Date 1976	Founding Date 2013
Type	Type Public	Type Private	Type Public	Type Private	Type Subsidiary
Tags	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma	Tags Healthcare drug development oncology pharma
Locations	Locations Pointe-Claire, CA HQ	Locations Lausanne, CH HQ Oss, NL	Locations Cambridge, US HQ	Locations Pazzallo, CH HQ Shanghai, CN Monaco, MC Biasca, CH Woodbridge Township, US	Locations San Diego, US HQ
Employees	Employees 5218% increase	Employees 4771% decrease	Employees 53611% increase	Employees 3731% decrease	Employees 474% decrease
Valuation ($)	Valuation ($) 5.8 m	Valuation ($) N/A	Valuation ($) 2.7 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $36.3m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $54m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $30.8m (FY, 2021)
Cost of goods	Cost of goods $24.1m (FY, 2025)	Cost of goods N/A	Cost of goods $6.3m (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit $12.3m (FY, 2025)	Gross profit N/A	Gross profit $47.7m (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income ($6m) (FY, 2025)	Net income N/A	Net income ($412.8m) (FY, 2025)	Net income N/A	Net income ($236.6m) (FY, 2021)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 2.1m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 144.4m